People: Crucell NV (CRXL.O)

CRXL.O on Nasdaq

19.59USD
9 Feb 2010
Price Change (% chg)

$0.40 (+2.08%)
Prev Close
$19.59
Open
--
Day's High
$19.65
Day's Low
$19.06
Volume
157,578
Avg. Vol
111,397
52-wk High
$25.53
52-wk Low
$17.50

view people for:

Summary

Name Age Since Current Position
Oosterveld, Jan 65 2006 Chairman of the Supervisory Board
Brus, Ronald 46 2004 Chairman of the Management Committee and Management Board, President & Chief Executive Officer
Lance, Sean 62 Vice Chairman of the Supervisory Board
Kruimer, Leonard 51 2005 Member of the Management Committee and Management Board, Chief Financial Officer
De Jong, Cees 48 2008 Member of the Management Committee, Member of the Management Board, Chief Operating Officer
Lahr, Arthur 41 2006 Member of the Management Committee, EVP Business Development, Chief Strategy Officer
Goudsmit, Jaap 58 2004 Member of the Management Committee and Management Board, Chief Scientific Officer, Head of Research and Development
Beukema, Rene 45 General Counsel and Corporate Secretary, Member of the Management Committee
Sjostrand, Bjorn 41 Member of the Management Committee,Chief Business Officer
Satow, Phillip 67 Member of the Supervisory Board
Wilhelmsson, Claes 70 2003 Member of the Supervisory Board
Hoevenaars, Arnold 60 2005 Member of the Supervisory Board
Davis, Steve 51 2008 Member of the Supervisory Board
Waller, Floris 50 2009 Member of the Supervisory Board
» Insider Trading

Biographies

Name Description
Oosterveld, Jan Prof.Dr. Jan Pieter Oosterveld is Chairman of the Supervisory Board and Member of the Remuneration Committee of Crucell N.V. Prof. Oosterveld has served as Member of Crucell's Supervisory Board since May 2004 and was appointed as Chairman on June 2, 2006. He retired from Royal Philips Electronics N.V. on April 1, 2004, after an international career of 32 years. He was responsible for Corporate Strategy, Corporate Alliances and the joint ventures with LGE on CRT and LCD. In the latter responsibility he was Chairman of the Board of LG.Philips Ltd, which went public in April 2004 and Vice-Chairman of the Board of LG.Philips Displays BV. He was also Chief Executive Officer of Philips Asia Pacific. He graduated as a Mechanical Engineer from the Technische Universiteit Eindhoven (Technical University Eindhoven), and holds an MBA from the Instituto de Estudios Superiores de la Empresa (IESE) in Barcelona. He was appointed Professor at IESE in 2003. He is also a Member of the Board of Barco, Kortrijk, Belgium, Cookson Group, London, United Kingdom, Candover, London, United Kingdom and Continental, Hannover, Germany.
Brus, Ronald Dr. Ronald H.P. Brus is Chairman of the Management Committee, Chairman of the Management Board, President and Chief Executive Officer of Crucell N.V. He has been a Member of Crucell’s Management Committee since the Company’s incorporation and was formerly Chief Operating Officer (March 2003 to January 2004) and Chief Business Officer (October 2000 to February 2003). Prior to that, he was Executive Vice President Business Development after joining the Company in 1997. From 1994 to 1996 he was product planning physician at Forest Laboratories in New York and from 1990 to 1994 he was Medical Director for Zambon B.V.He holds a Medical Degree (M.D.) from the Rijksuniversiteit Groningen (State University of Groningen).
Lance, Sean Mr. Sean P. Lance is Vice Chairman of the Supervisory Board and Member of the Audit Committee of Crucell N.V. He was first appointed as Member on January 1, 2004. Mr. Lance is former Chairman of Chiron Corporation. He joined Chiron as President and Chief Executive Officer in 1998. From 1985 to 1998 he was employed at Glaxo Holdings where his last position was group Chief Operating Officer and Chief Executive Officer designate. He is former President of the International Federation of Pharmaceutical Manufacturers Association. Mr. Lance is Chartered Company Secretary and Administrator and also holds a post-graduate qualification in Advanced Financial Management.
Kruimer, Leonard Mr. Leonard Kruimer is Member of the Management Board, Member of the Management Committee and Chief Financial Officer of Crucell N.V. has been Chief Financial Officer, since he joined Crucell in 1998. Mr. Kruimer became a Member of the Management Board in January 2005. Prior to Crucell, he held interim executive positions at Pepsico and Royal Boskalis Westminster. From 1993 to 1995, he was Managing Director Continental Europe at TIP Europe, a unit of GE Capital. Prior he held senior executive positions at Kwik-Fit Europe and Continental Can Europe. He was a consultant with McKinsey & Co and started his career at PriceWaterhouse & Co in New York. He holds an MBA from the Harvard Graduate School of Business Administration and an undergraduate degree from the University of Massachusetts. He is a CPA in New York State.
De Jong, Cees Dr. Cees De Jong is Chief Operating Officer, Member of the Management Board and Member of the Management Committee of Crucell N.V. He joined Crucell as Chief Operating Officer on September 10, 2007. He was already part of Crucell’s Management Committee, prior to his nomination to become a Member of Crucell’s Management Board on May 30, 2008. Prior he worked at Quest International in Naarden, the Netherlands, as a Member of the Board responsible for the Flavours Division. Prior to Quest, he worked as Managing Director of DSM Anti-infectives. In 1989 he started his career at Gist Brocades, holding a variety of roles in Business Development, Strategy and General Management before the company’s acquisition by DSM in 1998. He holds a medical degree and earned an MBA both from the Erasmus Universiteit Rotterdam
Lahr, Arthur Mr. Arthur Lahr is Member of the Management Committee, Executive Vice President Business Development and Chief Strategy Officer of Crucell N.V. He was appointed Vice President of Business Development in December 2003 and Member of the Management Committee in January 2004. He joined Crucell in April 2001 as Executive Director, Business Development. From 1994 to 2001 he was Consultant at McKinsey & Co. in the Netherlands and New York. Prior to that, Mr. Lahr worked with Unilever. He holds a Masters in Business Administration from INSEAD and a Masters in Science, Applied Physics, from the Delft University of Technology.
Goudsmit, Jaap Prof. Dr. Jaap Goudsmit is Member of the Management Committee, Member of the Management Board, Chief Scientific Officer and Head of Research and Development of Crucell N.V. He became a Member of Crucell’s Management Board in January 2004. He joined Crucell in 2001 as Senior Vice President Vaccine Research and became a Member of Crucell’s Management Committee in July 2002. He chaired at the Academic Medical Center of the University of Amsterdam the Research Institute for Infectious Diseases and the Institute for Science Education. He was the founding Chair of the Scientific Advisory Committee of the International AIDS Vaccine Initiative (IAVI) and the founding Co-Chair of the European Vaccine Effort against HIV/AIDS (EuroVac). Since 1989 he has been Professor at the University of Amsterdam and the Academic Medical Center. He holds a medical degree (MD) and a Ph.D. from the Universiteit van Amsterdam and is a board certified medical microbiologist.
Beukema, Rene Mr. Rene K. Beukema is General Counsel, Corporate Secretary and Member of the Management Committee of Crucell N.V. since the Company’s incorporation. He held the same position at IntroGene from 1999 to 2000. From 1994 to 1999, Mr. Beukema was Senior Legal Counsel for GE Capital/TIP Europe. Prior to that, he was Legal Counsel for TNT Express Worldwide N.V. from 1991 to 1994. Mr. Beukema holds a Masters degree in Law from the Universiteit van Amsterdam (University of Amsterdam).
Sjostrand, Bjorn Mr. Bjorn Sjostrand is Member of the Management Committee and Chief Business Officer of Crucell N.V. He was Chief Executive Officer at SBL Vaccines before it merged with Crucell in November 2006. Mr. Sjostrand successfully headed the Crucell-SBL Integration Committee while directing the travel franchise and the Nordic sales force for the Crucell Group. He initiated and led a Management buyout of SBL Vaccin AB funded by 3i and SEB Foretagsinvest. Between 1999 and 2001, he was Vice President Operations & IT at Active Biotech, where he was also Member of the Senior Management Team. Mr. Sjostrand completed a Bachelor of Science degree in Economics and Business Administration at the Orebro Universitet (University of Orebro). He also studied Financial Investment theory and Commercial law at the same university.
Satow, Phillip Mr. Phillip M. Satow is Member of the Supervisory Board and Chairman of the Remuneration Committee of Crucell N.V. He has served as Member of the Supervisory Board since the Company's incorporation. He spent 14 years at Pfizer, Inc. where his last position was Vice President, Pfizer Europe. From 1985 to 1997, he was Executive Vice President of Marketing at Forest Laboratories, Inc. From 1998 to 1999 he was President of Forest Pharmaceuticals, and Executive Vice President of Forest Laboratories Inc. In addition to the Forest Laboratories Board which he served on from 1999 to 2005, Mr. Satow is a former Board member of Eyetech Pharmaceuticals Inc. Mr. Satow co-founded, and served as Chairman and CEO of JDS Pharmaceuticals LLC, a privately held company that was sold to Noven Pharmaceuticals Inc. in 2007. Mr. Satow is currently a Member of the Board of Directors of Noven Inc.. He received a Masters of Arts in Economics from Georgetown University and a Bachelor of Arts form Columbia University.
Wilhelmsson, Claes Dr. Claes E. Wilhelmsson is Member of the Supervisory Board of Crucell N.V. and Member of the Remuneration Committee. He was appointed in May 2003. He was previously Member of the Board and Executive Director of Research and Development of AstraZeneca PLC from 1999 to July 2002, where he was responsible for AstraZeneca's global R&D. He joined Astra in 1985 and held various positions until the company merged with Zeneca in 1999. Prior to Astra, he was Lecturer and Researcher at the University of Goteborg in Sweden, where he also completed his medical education and Ph.D. Dr. Wilhelmsson currently serves on the Boards of a number of biotechnology and start-up companies. Dr. Wilhelmsson is Chairman of the Scientific Advisory Committee.
Hoevenaars, Arnold Mr. Arnold Hoevenaars is Member of the Supervisory Board and Chairman of the Audit Committee of Crucell N.V. He had been attending the Supervisory Board meetings as an Observer since July 2004, and was officially appointed to the Board at the AGM on June 2, 2005. Mr. Hoevenaars is Chartered Accountant in the Netherlands, and his previous positions include, among others, Chairman of the Management Board of the Achmea Group, Chairman of the Board of Directors and Chairman/Chief Executive Officer of the Executive Board of Eureko B.V. and Member of the Management Board and Chief Financial Officer of Royal Boskalis Westminster N.V.
Davis, Steve Mr. Steve Davis is Member of the Supervisory Board of Crucell N.V. He was appointed during the Company’s General Meeting of Shareholders on May 30, 2008 and has served as a Member since June 2008. Mr. Davis is a Senior Advisor to McKinsey & Company’s Social Sector Office based in Seattle, Washington, United States. He is also a Lecturer in Intellectual Property at the University of Washington Law School. He recently served as the Interim CEO of IDRI (Infectious Disease Research Institute) and is now Chairman of its Board of Directors. Previously, Mr. Davis was CEO of Corbis Corporation and presently acts as a senior advisor to the company. He has held positions with the United Nations High Commission for Refugees and several refugee resettlement programs. Currently, he is a Member of the Board of Trustees for PATH, a non-profit organization focused on improving public health in the developing world, and the Fred Hutchinson Cancer Research Center, one of the world’s leading cancer centers. He also holds board positions with Intrepid Learning Solutions, The Seattle Foundation and Global Partnerships. Mr. Davis holds a Bachelor of Arts from Princeton University, a Master of Arts from the University of Washington and a Doctorate in Law from Columbia University School of Law.
Waller, Floris

Basic Compensation

Name Fiscal Year Total
Oosterveld, Jan 54,200
Brus, Ronald 883,000
Lance, Sean 34,000
Kruimer, Leonard 535,000
De Jong, Cees 337,000
Lahr, Arthur --
Goudsmit, Jaap 585,000
Beukema, Rene --
Sjostrand, Bjorn --
Satow, Phillip 35,000
Wilhelmsson, Claes 35,000
Hoevenaars, Arnold 35,000
Davis, Steve 34,000
Waller, Floris --
As Of 30 Dec 2008

Insider Trading

» Full list on Insider Trading
view people for: